Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Universitaetsklinikum Heidelberg

Deutsches Krebsforschungszentrum

Ruprecht-Karls-Universitat Heidelberg

Ignacio Sancho-Martinez

Susanne Kleber

Peter Krammer

Christel Herold-Mende

Ana Martin-Villalba

Benedikt Wiestler

Thilo Welsch

Ana Martin-Vilalba

Peter Herhaus

The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo

The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament.

Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer

Growing community of inventors

Heidelberg, Germany

Ignacio Sancho-Martinez